- Home
- PCH vs APLS Comparison
PCH vs APLS Comparison
Compare PCH & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCH | APLS |
|---|---|---|
| Founded | 1903 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PCH | APLS |
|---|---|---|
| Price | $40.80 | $24.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $45.67 | $33.11 |
| AVG Volume (30 Days) | 508.7K | ★ 2.2M |
| Earning Date | 01-26-2026 | 10-30-2025 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ 312.61 | N/A |
| EPS | ★ 0.82 | 0.36 |
| Revenue | ★ $1,115,571,000.00 | $1,016,397,000.00 |
| Revenue This Year | $3.38 | $29.00 |
| Revenue Next Year | $1.91 | N/A |
| P/E Ratio | ★ $49.63 | $69.71 |
| Revenue Growth | 5.40 | ★ 42.11 |
| 52 Week Low | $36.82 | $16.10 |
| 52 Week High | $48.12 | $35.71 |
Technical Indicators
Market Signals| Indicator | PCH | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 66.56 |
| Support Level | $39.02 | $23.54 |
| Resistance Level | $40.14 | $24.45 |
| Average True Range (ATR) | 0.94 | 0.91 |
| MACD | 0.24 | 0.62 |
| Stochastic Oscillator | 69.86 | 87.25 |
Price Performance
Historical ComparisonAbout PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.